Cipher Pharmaceuticals Company Executives
| CPH Stock | CAD 15.35 0.36 2.40% |
Cipher Pharmaceuticals employs about 7 people. The company is managed by 7 executives with a total tenure of roughly 5 years, averaging almost 0.0 years of service per executive, having 1.0 employees per reported executive. Analysis of Cipher Pharmaceuticals' management performance can provide insight into the firm performance.
| Craig Mull Chairman Interim Chairman |
Cipher |
Cipher Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of 0.0506 % which means that it generated a profit of $0.0506 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1798 %, meaning that it generated $0.1798 on every $100 dollars invested by stockholders. Cipher Pharmaceuticals' management efficiency ratios could be used to measure how well Cipher Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 2nd of December 2024, Return On Tangible Assets is likely to grow to 0.31. Also, Return On Capital Employed is likely to grow to 0.15. At this time, Cipher Pharmaceuticals' Debt To Assets are very stable compared to the past year. As of the 2nd of December 2024, Return On Assets is likely to grow to 0.25, while Total Assets are likely to drop about 46.4 M.As of the 2nd of December 2024, Common Stock Shares Outstanding is likely to grow to about 32.1 M. Also, Net Income Applicable To Common Shares is likely to grow to about 32.2 M
Cipher Pharmaceuticals Workforce Comparison
Cipher Pharmaceuticals is currently under evaluation in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 760. Cipher Pharmaceuticals adds roughly 0.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Cipher Pharmaceuticals Profit Margins
The company has Profit Margin (PM) of 0.6 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.18 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.18.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.95 | 0.8077 |
|
|
Cipher Pharmaceuticals Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Cipher Pharmaceuticals Price Series Summation is a cross summation of Cipher Pharmaceuticals price series and its benchmark/peer.
Cipher Pharmaceuticals Notable Stakeholders
A Cipher Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Cipher Pharmaceuticals often face trade-offs trying to please all of them. Cipher Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Cipher Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Craig Mull | Interim Chairman | Profile | |
| Emilio Presti | Director Marketing | Profile | |
| Hamed Ghanei | Chief Officer | Profile | |
| Bryan Jacobs | Chief Officer | Profile | |
| Diane Gajewczyk | Vice Affairs | Profile | |
| Chuoru Li | Co Controller | Profile | |
| David Miller | Director Fin | Profile |
About Cipher Pharmaceuticals Management Performance
The success or failure of an entity such as Cipher Pharmaceuticals often depends on how effective the management is. Cipher Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Cipher management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Cipher management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.30 | 0.31 | |
| Return On Capital Employed | 0.14 | 0.15 | |
| Return On Assets | 0.24 | 0.25 | |
| Return On Equity | 0.25 | 0.27 |
Cipher Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Cipher Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Cipher Pharmaceuticals within its industry.Cipher Pharmaceuticals Manpower Efficiency
Return on Cipher Pharmaceuticals Manpower
| Revenue Per Employee | 3M | |
| Revenue Per Executive | 3M | |
| Net Income Per Employee | 2.9M | |
| Net Income Per Executive | 2.9M | |
| Working Capital Per Employee | 6.1M | |
| Working Capital Per Executive | 6.1M |
Other Information on Investing in Cipher Stock
Cipher Pharmaceuticals financial ratios help investors to determine whether Cipher Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cipher with respect to the benefits of owning Cipher Pharmaceuticals security.